VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. - Wikidata - awgldk - TriplyDB

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.

http://www.wikidata.org/entity/Q34981147

about

Current and emerging treatment strategies for Duchenne muscular dystrophy Clinical utility of serum biomarkers in Duchenne muscular dystrophy Duchenne Muscular Dystrophy: From Diagnosis to Therapy Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors Pregnancy-induced amelioration of muscular dystrophy phenotype in mdx mice via muscle membrane stabilization effect of glucocorticoid Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion.A Reduction in Selenoprotein S Amplifies the Inflammatory Profile of Fast-Twitch Skeletal Muscle in the mdx Dystrophic Mouse.Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor.Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.Exclusion of the unfolded protein response in light-induced retinal degeneration in the canine T4R RHO model of autosomal dominant retinitis pigmentosa.Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study ECG in neonate mice with spinal muscular atrophy allows assessment of drug efficacy.Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling Pathway Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014 Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice.Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy.Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.Establishment of a highly sensitive sandwich ELISA for the N-terminal fragment of titin in urine Current Translational Research and Murine Models For Duchenne Muscular Dystrophy.Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease.Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy.Drug Discovery of Therapies for Duchenne Muscular Dystrophy.Immune-mediated pathology in Duchenne muscular dystrophy.Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb Girdle Muscular Dystrophy.Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.Critical Illness Myopathy (CIM) and Ventilator-Induced Diaphragm Muscle Dysfunction (VIDD): Acquired Myopathies Affecting Contractile Proteins.Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.Human interstitial cellular model in therapeutics of heart valve calcification.

P2860

Q26741535-5252EF50-7A33-44CE-B67F-84715B626623 Q26751261-E36F558A-FB19-493A-A11C-44B381656395 Q26784259-D72AEF4C-2D1F-47DB-B4BB-4F84A9F01EAD Q28069464-1DF65863-176D-424C-B763-1FB3102277D7 Q28544401-C43CC119-AEB4-44BE-A4F4-64F1087C31D6 Q28544896-F946FCEF-3647-4770-8E58-364508DC061B Q30582564-1166E1FC-24D0-4C5B-8E80-C72D46F4814B Q33737817-14ABB037-EB2C-4D22-B5E3-28E23BB65A22 Q33809437-615080E9-D3B0-4E67-A181-D58C256479B4 Q34152280-90407A9F-185C-47B7-9283-B80689BFC292 Q34332718-0355A0E7-ED0E-471C-97C8-A9CA8CF06A55 Q34548198-E888DF7A-4601-4869-B247-676BBD665B0E Q34555477-B40A5FE9-AB23-4112-A5D1-E4667855E172 Q35103311-A8A68F4C-D1F7-4F40-B220-4902C95ED076 Q35495274-1B634A49-3034-49F8-9F51-F10182F74E96 Q35530447-7947C791-65ED-4828-AF5E-563CAC920F72 Q35740280-BE3EF1D4-56E1-4FD0-82DA-3CB7DCC1D3B4 Q35821127-D3336F9D-EDD7-4F8E-BB3B-E8E457D14972 Q35853255-17A4307A-FE58-47B8-8D6A-B276BCEDCBF9 Q35859481-66A0F40D-D7E3-4812-A759-07813084EEDE Q35869849-CEBB3F58-D167-4E45-BA04-485BF7445BD1 Q36026239-F89B24DE-6644-4ABE-8C5C-B02DD41EC055 Q36155677-B09CD148-A7E2-4FA7-A8AA-F496137CE3A6 Q36223929-0502B413-C9EA-48D1-8A76-22C007B20400 Q36590389-F4A8FCD8-4C57-408A-813E-E562974CB47A Q37181580-2A05CED8-9E5E-4DA9-AB2F-4C1E882167F1 Q37372312-81D96C81-3FB5-4A54-BE9C-9544EC1A0563 Q37395745-A7207EAF-3246-4A49-B5AD-FFA8C5AB8149 Q37518858-4E7182CF-7FD1-42AF-B32D-20E7157039C7 Q37610505-BC2D64B3-2B38-4300-A775-7DAC597A0712 Q37620348-9BB133A5-3C9F-44D9-B194-F9F6716A7651 Q37633713-BE1811AC-165B-4CBA-9DA2-7FC7665C501E Q38480698-77372B7D-04EA-4A24-A63C-D5A363BB69FA Q38561435-C613A748-A591-4FA9-AD85-30B866D9ABD4 Q38617041-1C8C64B2-FFE5-4690-8BD4-97CDF66E4A7F Q38825776-D88927B4-5897-4EB8-92C0-B193D5742C77 Q39109406-CACBDBCC-CE44-42ED-BD54-F7FA8CBECAD4 Q39115626-2B0FA399-1F9C-4B2D-B5F0-A00DFF524F2E Q39158020-1A181DA1-7030-438F-B54B-DE0D166C37B8 Q39325703-1F59F2BE-4E83-46AD-9889-280BCD8444C6

P2860

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.

http://www.wikidata.org/entity/Q34981147

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@ast

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@en

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@nl

type

label

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@ast

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@en

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@nl

prefLabel

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@ast

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@en

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@nl

P1433

Q34981147-4A52026A-26C7-4D83-A62F-95C442C012A6

P1476

Q34981147-C3C8D861-BC40-4E7C-8D97-5E6EE0F48A55

P2093

Q34981147-0C8E90F7-5CC5-419D-8762-833776EBDC84

Q34981147-31AB4146-A6D9-49F0-85AB-B9D302151625

Q34981147-35FE537C-5A9B-4BDE-BCFF-A36285F07B3C

Q34981147-459C3612-4F41-4281-B43E-E69917D17898

Q34981147-5A50E694-F6D9-49D0-9A45-318CFC17882B

Q34981147-71E25A57-81E6-4234-A099-44F267274F74

Q34981147-75CA1F9E-F744-4AE9-A891-DDBE940C938A

Q34981147-854C7FFD-D588-4905-ADB7-6147019FD3D5

Q34981147-89E26DCE-F049-45FE-AA01-1CBED7E4D0B9

Q34981147-A2A8548D-2AFA-4744-862C-221C1D895290

P2860

Q34981147-0362BC2F-6A47-4076-861F-75EBB5444382

Q34981147-04B28083-0DB5-482E-9C74-1BF6416ED5F3

Q34981147-071158FA-4553-420A-A823-F577245C2273

Q34981147-07526E22-D920-4B4E-AE17-8ACD5A8759BD

Q34981147-0837BEB5-48C8-431E-B915-CFF30E17E2C2

Q34981147-23495E24-F18B-49B1-ACC1-FF051F4A8897

Q34981147-24EE93F9-EDC8-4330-A20D-BBDB40650798

Q34981147-266F0AEF-54F6-42E4-88DB-C42DCF417750

Q34981147-2890F8EA-74FE-4ED2-8F6B-747270882EF0

Q34981147-31A2FA7A-34D2-4A90-8E14-A6B753BB38A7

P304

Q34981147-F0ADC8F1-94CF-4BCB-A8B5-FD7D5D3A5690

P31

Q34981147-BAACD086-4640-4EE7-BFF3-24D25B4A06E7

P356

Q34981147-8CCA9DB7-61EE-4C9C-87AB-2EA16CF21D46

P433

Q34981147-15150E39-1BE1-45B8-954C-4E5EA9EF701C

P478

Q34981147-1B9F1FF7-9969-4248-926C-FC0293234AAE

P50

Q34981147-322E9EB5-14A4-4DF7-8EA2-82DA9D0C9927

Q34981147-49B9FDDA-03F2-4235-B4B0-814747592752

Q34981147-BCBB67E7-D02F-42DB-83B9-1C3B16323C99

Q34981147-CA5DA42B-2E06-4C89-85BD-73402BFD5031

Q34981147-F865E3C5-171C-424E-8078-33F0AE13CEF8

P577

Q34981147-6D14B41C-A743-47BD-83C9-C55B79C538A0

P5875

Q34981147-F5D7BB12-E8DE-4A81-8FD4-3A598B850AB2

P698

Q34981147-9D359B6B-9C88-4891-A634-6609D70C5667

P932

Q34981147-168EAF73-F048-4E8F-AC23-6FB5B246C3AB

P356

P1433

EMBO Molecular Medicine

P1476

VBP15, a novel anti-inflammato ...... ystrophy without side effects.

@en

P2093

Aditi Phadke

http://www.w3.org/2001/XMLSchema#string

Arpana Sali

http://www.w3.org/2001/XMLSchema#string

Brittany K Miller

http://www.w3.org/2001/XMLSchema#string

Chris Albanese

http://www.w3.org/2001/XMLSchema#string

Edward M Connor

http://www.w3.org/2001/XMLSchema#string

Eric P Hoffman

http://www.w3.org/2001/XMLSchema#string

Erica K M Reeves

http://www.w3.org/2001/XMLSchema#string

Heather Gordish-Dressman

http://www.w3.org/2001/XMLSchema#string

Jack H Van der Meulen

http://www.w3.org/2001/XMLSchema#string

James Quinn

http://www.w3.org/2001/XMLSchema#string

P2860

A call for transparent reporting to optimize the predictive value of preclinical research

Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy

DNA Binding Site Sequence Directs Glucocorticoid Receptor Structure and Activity

Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy

Defective membrane repair in dysferlin-deficient muscular dystrophy

A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice

Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy

Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse

Hsp72 preserves muscle function and slows progression of severe muscular dystrophy

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.

P304

1569-1585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.201302621

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Kanneboyina Nagaraju

Christopher Heier

Jyoti K. Jaiswal

Blythe C Dillingham

P577

2013-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256469948

http://www.w3.org/2001/XMLSchema#string

P698

24014378

http://www.w3.org/2001/XMLSchema#string

P932

3799580

http://www.w3.org/2001/XMLSchema#string